- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
US Teen Substance Use in 2021: A True/False Quiz
How many high school students report current alcohol use? Are boys more likely than girls to use marijuana? Answers and more in our 5-question quiz.
The US Centers for Disease Control and Prevention (CDC) recently published the Youth Risk Behavior Survey Data Summary & Trends Report: 2011–2021, which monitors priority health risks and experiences among youth across the US including sexual risk behaviors, mental health, tobacco use, and more. In the 5 questions below, we focus on the update addressing substance use behaviors among high school students (grades 9-12) between 2011 and 2021. Substance use variables included the percentage of youth who drank alcohol, used marijuana, or used electronic vapor products during the past 30 days (ie, current use); the percentage of students who ever used select illicit drugs, defined as cocaine, inhalants, heroin, methamphetamines, hallucinogens, or ecstasy; and the percentage of students who misused prescription opioids (eg, Vicodin, OxyContin, Hydrocodone) either ever in their lifetime or during the past 30 days.
Have prevalence rates decreased? Take the quiz for key results.
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
December 23rd 2025The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
